321 related articles for article (PubMed ID: 27232955)
1. Optimization of a novel series of pyranopyridine RND efflux pump inhibitors.
Aron Z; Opperman TJ
Curr Opin Microbiol; 2016 Oct; 33():1-6. PubMed ID: 27232955
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives.
Sjuts H; Vargiu AV; Kwasny SM; Nguyen ST; Kim HS; Ding X; Ornik AR; Ruggerone P; Bowlin TL; Nikaido H; Pos KM; Opperman TJ
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):3509-14. PubMed ID: 26976576
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel pyranopyridine inhibitor of the AcrAB efflux pump of Escherichia coli.
Opperman TJ; Kwasny SM; Kim HS; Nguyen ST; Houseweart C; D'Souza S; Walker GC; Peet NP; Nikaido H; Bowlin TL
Antimicrob Agents Chemother; 2014; 58(2):722-33. PubMed ID: 24247144
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of a novel pyranopyridine series of Gram-negative bacterial efflux pump inhibitors.
Nguyen ST; Kwasny SM; Ding X; Cardinale SC; McCarthy CT; Kim HS; Nikaido H; Peet NP; Williams JD; Bowlin TL; Opperman TJ
Bioorg Med Chem; 2015 May; 23(9):2024-34. PubMed ID: 25818767
[TBL] [Abstract][Full Text] [Related]
5. The hydrophobic trap-the Achilles heel of RND efflux pumps.
Aron Z; Opperman TJ
Res Microbiol; 2018; 169(7-8):393-400. PubMed ID: 29146106
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of MBX2319 inhibition of Escherichia coli AcrB multidrug efflux pump and comparison with other inhibitors.
Vargiu AV; Ruggerone P; Opperman TJ; Nguyen ST; Nikaido H
Antimicrob Agents Chemother; 2014 Oct; 58(10):6224-34. PubMed ID: 25114133
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistant Acinetobacter baumannii--the role of AdeABC (RND family) efflux pump in resistance to antibiotics.
Wieczorek P; Sacha P; Hauschild T; Zórawski M; Krawczyk M; Tryniszewska E
Folia Histochem Cytobiol; 2008; 46(3):257-67. PubMed ID: 19056528
[TBL] [Abstract][Full Text] [Related]
8. High-Throughput Flow Cytometry Screening of Multidrug Efflux Systems.
Haynes MK; Garcia M; Peters R; Waller A; Tedesco P; Ursu O; Bologa CG; Santos RG; Pinilla C; Wu TH; Lovchik JA; Oprea TI; Sklar LA; Tegos GP
Methods Mol Biol; 2018; 1700():293-318. PubMed ID: 29177837
[TBL] [Abstract][Full Text] [Related]
9. RND efflux pump mediated antibiotic resistance in Gram-negative bacteria Escherichia coli and Pseudomonas aeruginosa: a major issue worldwide.
Puzari M; Chetia P
World J Microbiol Biotechnol; 2017 Feb; 33(2):24. PubMed ID: 28044273
[TBL] [Abstract][Full Text] [Related]
10. Characterization of substituted piperazines able to reverse MDR in Escherichia coli strains overexpressing resistance-nodulation-cell division (RND) efflux pumps.
Casalone E; Vignolini T; Braconi L; Gardini L; Capitanio M; Pavone FS; Giovannelli L; Dei S; Teodori E
J Antimicrob Chemother; 2022 Feb; 77(2):413-424. PubMed ID: 34747445
[TBL] [Abstract][Full Text] [Related]
11. Efflux pump genes of the resistance-nodulation-division family in Burkholderia cenocepacia genome.
Guglierame P; Pasca MR; De Rossi E; Buroni S; Arrigo P; Manina G; Riccardi G
BMC Microbiol; 2006 Jul; 6():66. PubMed ID: 16857052
[TBL] [Abstract][Full Text] [Related]
12. Recent advances toward a molecular mechanism of efflux pump inhibition.
Opperman TJ; Nguyen ST
Front Microbiol; 2015; 6():421. PubMed ID: 25999939
[TBL] [Abstract][Full Text] [Related]
13. Pyrrole-based inhibitors of RND-type efflux pumps reverse antibiotic resistance and display anti-virulence potential.
Mahey N; Tambat R; Kalia R; Ingavale R; Kodesia A; Chandal N; Kapoor S; Verma DK; Thakur KG; Jachak S; Nandanwar H
PLoS Pathog; 2024 Apr; 20(4):e1012121. PubMed ID: 38593161
[TBL] [Abstract][Full Text] [Related]
14. Pyridylpiperazine-based allosteric inhibitors of RND-type multidrug efflux pumps.
Plé C; Tam HK; Vieira Da Cruz A; Compagne N; Jiménez-Castellanos JC; Müller RT; Pradel E; Foong WE; Malloci G; Ballée A; Kirchner MA; Moshfegh P; Herledan A; Herrmann A; Deprez B; Willand N; Vargiu AV; Pos KM; Flipo M; Hartkoorn RC
Nat Commun; 2022 Jan; 13(1):115. PubMed ID: 35013254
[TBL] [Abstract][Full Text] [Related]
15. Comparative reassessment of AcrB efflux inhibitors reveals differential impact of specific pump mutations on the activity of potent compounds.
Schuster S; Vavra M; Wirth DAN; Kern WV
Microbiol Spectr; 2024 Feb; 12(2):e0304523. PubMed ID: 38170977
[TBL] [Abstract][Full Text] [Related]
16. RND efflux pumps: structural information translated into function and inhibition mechanisms.
Ruggerone P; Murakami S; Pos KM; Vargiu AV
Curr Top Med Chem; 2013; 13(24):3079-100. PubMed ID: 24200360
[TBL] [Abstract][Full Text] [Related]
17. Tripartite efflux pumps of the RND superfamily: what did we learn from computational studies?
Athar M; Gervasoni S; Catte A; Basciu A; Malloci G; Ruggerone P; Vargiu AV
Microbiology (Reading); 2023 Mar; 169(3):. PubMed ID: 36972322
[TBL] [Abstract][Full Text] [Related]
18. Bacterial multidrug efflux transporters.
Delmar JA; Su CC; Yu EW
Annu Rev Biophys; 2014; 43():93-117. PubMed ID: 24702006
[TBL] [Abstract][Full Text] [Related]
19. RND efflux pumps in Gram-negative bacteria; regulation, structure and role in antibiotic resistance.
Colclough AL; Alav I; Whittle EE; Pugh HL; Darby EM; Legood SW; McNeil HE; Blair JM
Future Microbiol; 2020 Jan; 15():143-157. PubMed ID: 32073314
[TBL] [Abstract][Full Text] [Related]
20. Kinetic analysis of the inhibition of the drug efflux protein AcrB using surface plasmon resonance.
Mowla R; Wang Y; Ma S; Venter H
Biochim Biophys Acta Biomembr; 2018 Apr; 1860(4):878-886. PubMed ID: 28890187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
